Viemed Healthcare | 144: Notice of proposed sale of securities pursuant to Rule 144
This document is a formal Notice of Proposed Sale of Securities pursuant to Rule 144 for Viemed Healthcare. It indicates an intention to sell securities under specific conditions set forth by the SEC rule, which allows for the sale of restricted and control securities without registration.
VMD - Viemed Healthcare Inc Dividends
This article provides a detailed financial overview of Viemed Healthcare Inc (VMD), including its latest stock performance, key financial metrics, and valuation ratios. It highlights the company's market capitalization, income, sales, and various profitability indicators, along with insider and institutional ownership data. The report also lists analyst recommendations and price targets.
Don't Ignore The Insider Selling In Viemed Healthcare
An independent director at Viemed Healthcare recently sold US$230k worth of shares, representing 21% of their holding. This follows a larger sale of US$1.2m by the President over the last year, with no insider buying observed. While Viemed Healthcare is profitable and growing, the consistent selling raises questions about the insiders' view on the stock's valuation, despite their current 14% ownership.
Don't Ignore The Insider Selling In Viemed Healthcare
An independent director at Viemed Healthcare, Timothy Smokoff, recently sold US$230k worth of shares, accounting for 21% of his holding. This follows a larger sale of US$1.2m by President Michael Moore in the past year when the share price was lower. Despite the company being profitable, the consistent insider selling without any corresponding buying raises caution among investors.
Viemed Healthcare | ARS: Annual Report to Security Holders
This document is an Annual Report to Security Holders for Viemed Healthcare. It provides a formal report on the company's activities and financial performance over the past year, as required for its security holders. The content of the report is simply referred to as "Document."
VMD - Viemed Healthcare Inc Earnings
This article provides a detailed financial overview of Viemed Healthcare Inc (VMD), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics like EPS growth, insider and institutional ownership, profitability margins, and stock performance over different periods. The data covers real-time stock information and historical financial statistics for potential investors.
Viemed Healthcare (VMD) director sells 20,000 common shares
Viemed Healthcare (VMD) director Timothy Smokoff sold 20,000 common shares on June 24, 2026, through five open-market transactions. The sales occurred at prices ranging from $11.41 to $11.56 per share, totaling approximately $230,000. These transactions were reported via a Form 4 SEC filing, and after the sales, Smokoff's direct holdings in Common Shares stand at 93,882.
Viemed Healthcare (VMD) CMO exercises options and sells 10,000 shares
Viemed Healthcare's Chief Medical Officer, William Frazier, executed an exercise-and-sell transaction involving 10,000 common shares. He exercised stock options at $1.81 per share and subsequently sold the shares in an open-market transaction at $11.72 per share, resulting in a net reduction of 10,000 common shares in his direct holdings. After these transactions, Frazier retains 73,214 common shares and 26,261 fully vested stock options expiring in 2028.
Viemed Healthcare, Inc. Actuals & Estimates (NASDAQ:VMD)
This article provides financial actuals and analyst estimates for Viemed Healthcare, Inc. (NASDAQ:VMD). It covers current stock performance, future price forecasts, historical highs and lows, market capitalization, and upcoming earnings dates, offering a detailed overview of the company's financial health and prospects.
Viemed Healthcare updates guidance and buyback, shares react to revised outlook
Viemed Healthcare has updated its 2025 revenue guidance and refreshed its share repurchase program in a recent investor presentation, targeting $500 million in annual revenue by 2030. The company reiterated its commitment to double-digit growth and balanced capital allocation between internal investments and shareholder returns. Analysts hold mixed views, acknowledged demographic tailwinds, competition and reimbursement risks with consensus price targets modestly above current quotation.
VMD Forecast — Price Target — Prediction for 2027
This article provides a forecast for Viemed Healthcare, Inc. (VMD) stock, including analyst price targets, historical performance, and financial data. One analyst projects a 1-year price target of $11.00 for VMD, with the stock currently trading at $11.69. The company's financial overview highlights recent earnings, revenue, market capitalization, and upcoming earnings report scheduled for August 12, 2026.
Viemed Healthcare Announces Third Quarter 2025 Financial Results
Viemed Healthcare, Inc. (NASDAQ:VMD) reported record net revenues of $71.9 million for Q3 2025, a 24% increase year-over-year, and net income of $3.5 million. The company completed its 2025 share repurchase program and strategically acquired Lehan’s Medical Equipment, contributing to strong patient count growth in ventilator and PAP therapy. Viemed updated its full-year 2025 financial guidance, narrowing net revenue expectations to $271-$273 million and Adjusted EBITDA to $60-$62 million.
Viemed Healthcare Inc (VMD) Valuation: PE, PB & Fair Value Analysis
Viemed Healthcare Inc (VMD) has a current valuation score of 6.10, placing it 67th out of 76 in the Healthcare Providers & Services industry. Its P/E ratio is 27.71, which is 171.83% below its recent high and 40.15% above its recent low. The company has not yet disclosed data for P/B, P/S, or P/CF ratios.
Viemed Healthcare Inc (VMD) Institutional Confidence
Viemed Healthcare Inc (VMD) currently holds an institutional shareholding score of 7.00, placing it 37th out of 76 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 72.39%, showing an 8.13% quarter-over-quarter increase. First Eagle Investment is the largest institutional shareholder with 493.43K shares, representing 1.37% of outstanding shares.
Viemed Healthcare Inc (VMD) Financial Health: Profitability & Balance Sheet Analysis
This article provides an analysis of Viemed Healthcare Inc's (VMD) financial health, ranking it highly within the Healthcare Providers & Services industry. The company's financial score is 8.43, indicating robustness and high operating efficiency. Key financial metrics covering quality of earnings, operational efficiency, growth potential, and shareholder returns are briefly highlighted.
Understanding Momentum Shifts in (VMD)
This article analyzes momentum shifts in Viemed Healthcare Inc. (VMD), indicating strong sentiment across all horizons and significant upside potential as no resistance levels remain. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis. The analysis suggests an overweight bias for VMD.
Viemed Healthcare Inc (VMD) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Viemed Healthcare Inc (VMD), outlining its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional holding trends from 2023Q4 to 2026Q1, and recent shareholder activity with changes in holdings for key investors. The report highlights that institutional ownership represents a significant portion of the company's shares.
Viemed Healthcare (Nasdaq: VMD) shareholders approve directors, pay and expanded 2024 LTIP
Viemed Healthcare shareholders approved key proposals at their Annual General and Special Meeting, including the election of all seven director nominees with strong support. They also backed a second amendment to the 2024 Long Term Incentive Plan, increasing reserved common shares to 7,696,717, and approved the appointment of Ernst & Young LLP as independent auditors. Additionally, executive compensation received significant advisory approval.
VMD Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes the financial performance of Viemed Healthcare Inc (VMD), focusing on its profitability margins and comparing them to competitors like CYH and BTMD. VMD maintains a gross margin of 56.27%, with an operating margin of 6.27% and a net margin of 3.60%. The company has a market capitalization of $363.43M.
VieMed Healthcare posts June 2026 investor deck with strong 2025 results and 2026 guidance
VieMed Healthcare (VMD) has released its investor deck for June 2026 presentations, highlighting record 2025 results and strong Q1 2026 momentum. The company reported $270.3M net revenue and $61.4M Adjusted EBITDA for 2025, with Q1 2026 showing continued growth in revenue and patient numbers. VieMed also provided 2026 guidance, projecting net revenue between $312M and $320M and Adjusted EBITDA from $65M to $69M, alongside a new share repurchase program.
Viemed Healthcare (VMD) touts 28% 2025 growth, strong cash flow and 2026 guidance
Viemed Healthcare reported robust financial performance in 2025, including $270 million in net revenue (up 28% year-over-year) and $28 million in free cash flow, alongside strong guidance for 2026 with projected net revenues of $312–$320 million. The company emphasizes its diversified service lines, capital-light model, and commitment to shareholder returns through a new share repurchase program, with effectively no net debt and significant credit facility availability. This success is built on a foundation of clinical excellence in home-based respiratory care and strategic expansion into adjacent markets.
VMD - Viemed Healthcare Inc Short Interest
This article provides a detailed financial overview of Viemed Healthcare Inc (VMD), including its current stock price, market capitalization, key financial ratios, and short interest data. It covers various performance metrics such as EPS, sales growth, insider and institutional ownership, and profitability margins. The data presented offers a snapshot of the company's financial health and market sentiment.
Top Growth Companies With Significant Insider Ownership May 2026
This article identifies top growth companies in the US market with significant insider ownership as of May 2026. It highlights the robust performance of the US market and the potential appeal of companies where insiders demonstrate strong confidence. The article details three specific companies – Viemed Healthcare (VMD), Better Home & Finance Holding (BETR), and Diana Shipping (DSX) – providing an overview, operational insights, insider ownership percentages, and earnings growth forecasts for each, along with a list of other companies meeting the criteria.
Discipline and Rules-Based Execution in VMD Response
This article provides key findings for Viemed Healthcare Inc. (NYSE: VMD), highlighting a near-term strong sentiment transitioning to a long-term positive bias with a mid-channel oscillation pattern. It outlines an exceptional short setup for VMD and presents three distinct AI-generated trading strategies with specific entry, target, and stop-loss levels for different risk profiles. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
Viemed Healthcare (VMD) Q1 Net Margin Stays Near 5% And Tests Bullish Profit Narratives
Viemed Healthcare (VMD) reported Q1 2026 revenue of US$75.4 million and EPS of US$0.07, maintaining a net margin near 5%. While the company has seen 21.2% trailing earnings growth, its steady quarterly EPS and reliance on government reimbursement for a significant portion of its revenue raise questions about its long-term profitability and ability to significantly increase its margins. The article discusses both bullish and bearish perspectives on VMD's valuation and profit trajectory, noting its 22x P/E is below peers and industry averages, with a DCF fair value significantly higher than its current share price.
Viemed Healthcare: Maintaining 'Buy' Rating Post Q1 On Improving Capital Efficiency
Viemed Healthcare (VMD) continues its strong performance, with shares increasing by 28% since January. This growth is fueled by a 28% surge in Q1 revenues to $75.41 million, exceeding expectations, and a raised 2026 revenue guidance to $312-$320 million. The company's strategic shift towards less capital-intensive services is enhancing capital efficiency and supporting sustainable free cash flow generation.
viemed healthcare, inc Earnings dates
This article provides the upcoming earnings date for Viemed Healthcare, Inc. (VMD.V), scheduling its Q3 earnings release for November 6, 2025, after market close. It also includes other recent business headlines and economic updates.
Viemed Healthcare stock (US92671H1068): Q1 earnings update and long?term growth drivers
Viemed Healthcare recently reported its Q1 2026 earnings, posting an EPS of approximately $0.06, which fell short of some market expectations but still indicated positive profitability. The company, specializing in home-based respiratory care, continues to focus on recurring revenue from ventilator rentals and respiratory therapy services. While facing margin pressures from growth investments, Viemed benefits from structural demand drivers like an aging population and a shift towards home-based care, though regulatory risks and competitive pressures remain key factors for investors to monitor.
Behavioral Patterns of VMD and Institutional Flows
This article analyzes the behavioral patterns and institutional flows for Viemed Healthcare Inc. (NYSE: VMD), indicating a positive near-term sentiment that may overcome a weak mid-term bias within a long-term strong trend. It highlights an exceptional 35.0:1 risk-reward setup targeting an 11.7% gain with only 0.3% risk. The analysis also provides AI-generated trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Viemed Healthcare, Inc. - Common Shares (NQ: VMD)
This article provides recent news headlines and press releases concerning Viemed Healthcare, Inc. (NASDAQ: VMD). It covers financial results announcements, earnings call details, analyst coverage updates by Stonegate Capital Partners, share repurchase programs, and conference presentations.
Viemed Healthcare Shows Improved Revenue Mix and Free Cash Flow in Q1 2026
Viemed Healthcare (NASDAQ: VMD) reported strong Q1 2026 results, indicating an improved revenue mix and significant growth in free cash flow. The company is successfully shifting away from traditional ventilator rentals towards higher-growth areas like sleep, resupply, and maternal health, leading to better capital efficiency. This strategic shift has positively impacted its financial performance, with free cash flow rising to $36.3 million.
Viemed Healthcare Shows Improved Revenue Mix and Free Cash Flow in Q1 2026
Viemed Healthcare (NASDAQ: VMD) reported strong Q1 2026 results, showing an improved revenue mix with growth in sleep, resupply, and maternal health services. This shift has led to better free cash flow conversion, with cash flow from operations increasing to $8.1 million and trailing twelve-month free cash flow rising to $36.3 million. The company's strategic focus on less capital-intensive areas is positively impacting its financial performance.
Viemed sleep patients up 57% as ventilator revenue share falls
Stonegate Capital Partners updated its coverage on Viemed Healthcare (NASDAQ: VMD) following its 1Q26 performance, noting stronger free cash flow and a strategic shift in revenue mix. The company saw significant growth in sleep and resupply patient numbers, with PAP patients up 57% year-over-year, while the reliance on ventilator rentals decreased. Despite ongoing pressure from ventilator turnover, Viemed's diversified approach and improved capital efficiency contributed to a positive outlook.
Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (VMD) 1Q26
Stonegate Capital Partners has updated its coverage on Viemed Healthcare, Inc. (VMD) following its Q1 2026 results. The report highlights improving growth quality through increased contributions from sleep, resupply, and maternal health, reducing reliance on ventilation. This shift is driving stronger free cash flow conversion for the company.
Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (VMD) 1Q26
Stonegate Capital Partners has updated its coverage on Viemed Healthcare, Inc. (VMD) following its Q1 2026 results. The report highlights improving growth quality with increased contributions from sleep, resupply, and maternal health services, which are reducing reliance on legacy ventilation and improving capital efficiency. Key takeaways include significantly improved free cash flow conversion and a better revenue mix, with PAP patient growth and new patient starts being clear growth drivers.
Viemed Healthcare Q1 2026 Earnings Call: Complete Transcript
Viemed Healthcare reported strong Q1 2026 results with revenue up 28% year-over-year to $75.4 million, driven by growth in sleep and maternal health segments. PAP therapy patients increased by 57%, and free cash flow significantly improved to $2.6 million. The company raised its full-year 2026 revenue guidance to $312 million-$320 million, expressing confidence in continued growth and increasing capital efficiency.
VMD SEC Filings - Viemed Healthcare Inc 10-K, 10-Q, 8-K Forms
This article provides a comprehensive overview of Viemed Healthcare Inc. (VMD) SEC filings available on Stock Titan. It details the types of filings investors can access, such as 10-K, 10-Q, and 8-K reports, and highlights the AI-generated summaries and analytics provided to help interpret these complex documents. The article also touches on recent significant 8-K disclosures and insider trading activities, making regulatory information more accessible.
Viemed Healthcare, Inc. (VMD) Q1 earnings miss estimates
This article states that Viemed Healthcare, Inc. (VMD) missed its Q1 earnings estimates. No further details are provided in the current content.
Viemed Healthcare, Inc. (NASDAQ:VMD) Q1 2026 Earnings Call Transcript
Viemed Healthcare, Inc. reported strong Q1 2026 results, with revenue up 28% year-over-year to $75.4 million, driven by significant growth in its sleep and maternal health segments. The company highlighted enhanced free cash flow, improved capital efficiency, and strategic diversification away from ventilator revenue dependency. Viemed also updated its full-year 2026 guidance, raising the lower end of its net revenue range to $312 million to $320 million, and reaffirms its adjusted EBITDA outlook.
Viemed Healthcare Down Over 8%, on Pace for Largest Percent Decrease in Almost a Year -- Data Talk
Viemed Healthcare (VMD) stock is currently down over 8%, putting it on track for its largest percentage decrease in nearly a year. This significant drop follows a previous session's gain, where the stock had risen over 5%.
Viemed Q1 2026 slides: 28% revenue growth masks earnings miss
Viemed Healthcare Inc. (NASDAQ:VMD) reported Q1 2026 results with 28% revenue growth but missed analyst expectations for earnings and revenue, leading to a premarket stock decline. The company highlighted strong growth in its sleep therapy and maternal health segments as part of its diversification strategy, alongside solid operating cash flow and a net-debt-free balance sheet. Despite the miss, management reaffirmed full-year guidance and expressed confidence in its strategic initiatives.
Earnings call transcript: Viemed Healthcare’s Q1 2026 results miss forecasts
Viemed Healthcare reported Q1 2026 earnings that missed analyst forecasts, with an EPS of $0.06 against an expected $0.09 and revenue of $75.41 million versus the $77.35 million forecast. Despite a 9.79% premarket stock decline, the company achieved 28% year-over-year revenue growth and a significant improvement in free cash flow, driven by strong performance in its sleep/PAP therapy and maternal health segments. Executives expressed confidence in their diversification strategy and ability to adapt to regulatory changes, while InvestingPro analysis suggests the stock may be undervalued.
Viemed Healthcare (NASDAQ:VMD) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS
Viemed Healthcare (NASDAQ:VMD) recently announced its quarterly earnings, reporting an EPS of $0.06, which missed the consensus estimate of $0.09 by $0.03. Despite the earnings miss, the company's revenue of $75.41 million slightly surpassed analysts' expectations of $74.40 million. Insider selling activity was noted, with insiders selling 136,802 shares totaling about $1.24 million in the last quarter, yet still retaining 20% ownership of the stock.
Viemed Healthcare, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
Viemed Healthcare, Inc. announced its earnings for the first quarter ended March 31, 2026. The company reported sales of $75.41 million, an increase from $59.13 million a year ago. However, net income slightly decreased to $2.58 million compared to $2.63 million in the same period last year, resulting in diluted earnings per share of $0.06, consistent with the previous year.
Viemed Healthcare (VMD) Q1 2026 revenue jumps 28% as guidance raised
Viemed Healthcare reported robust growth in Q1 2026, with net revenue increasing 28% year-over-year to $75.4 million and Adjusted EBITDA rising 12% to $14.3 million. The company generated strong operating and free cash flow while also repurchasing shares and reducing debt. As a result of this performance, Viemed raised and narrowed its full-year 2026 revenue guidance to between $312 million and $320 million, reaffirming its Adjusted EBITDA outlook.
Viemed Healthcare (Nasdaq:VMD) - Stock Analysis
Viemed Healthcare (VMD) is currently trading significantly below its estimated fair value with a market cap of US$373.3m. While earnings are forecast to grow by 30.76% annually, the company has seen significant insider selling and has flagged revenue and earnings growth as a major risk due to a 9.7% annual decline over the past five years. Recent reports show mixed financial results, with revenue exceeding expectations but EPS lagging, despite ongoing acquisition plans and share repurchase programs.
Viemed Q1 2026 Results: Revenue Up 28%, Guidance Raised
Viemed Healthcare announced strong financial results for Q1 2026, with net revenues increasing 28% to $75.4 million and adjusted EBITDA up 12% to $14.3 million. The company also raised its full-year 2026 revenue guidance to between $312 million and $320 million, reflecting favorable trends and a more capital-efficient business model. Viemed's CEO highlighted significant growth in sleep and maternal health, along with positive momentum in the ventilator business.
Viemed Healthcare Inc expected to post earnings of 9 cents a share - Earnings Preview
Viemed Healthcare Inc (VMD) is projected to report earnings of 9 cents per share. This financial forecast is provided by Refinitiv in an earnings preview, indicating an upcoming earnings announcement for the company.
Three Insider-Favored Growth Companies With High Ownership
This article highlights three growth companies with high insider ownership in the United States market: Viemed Healthcare (VMD), Ramaco Resources (METC), and Uxin (UXIN). It provides an overview of each company's operations, financial performance, and future growth forecasts, emphasizing that high insider ownership can signal strong internal confidence and alignment with shareholder interests. The article also notes the US market's recent flat performance but significant annual increase and forecasted earnings growth.
Three Insider-Favored Growth Companies With High Ownership
This article highlights three growth companies—Viemed Healthcare (VMD), Ramaco Resources (METC), and Uxin (UXIN)—that exhibit high insider ownership, indicating strong internal confidence. These companies operate in diverse sectors and show significant potential for earnings and revenue growth, despite some facing challenges like net losses or legal issues. The analysis emphasizes the strategic importance of high insider ownership as an alignment of interests with shareholders in a flat market.
